Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

FTSE 100 movers: Housebuilders lead equities higher

Tue, 23rd Aug 2016 13:58

(ShareCast News) - The FTSE 100 rose 0.66% to 6,873.69 points in afternoon trade on Tuesday, with housebuilders topping the London index.Persimmon led housebuilders higher after reporting a better-than-expected jump in first half profits. Pre-tax profit rose 29% to £352.3m in the six months to 30 June on a 12% increase in revenue to £1.49bn. Analysts at Deutsche Bank had anticipated a 26% increase in pre-tax profits to £345m.Tesco rallied after Kantar Worldpanel said sales in the 12 weeks ending on 14 August fell 0.4%, albeit at the slowest rate of decline in six months. Fraser McKevitt, head of retail and consumer insight at Kantar, said the drop in Tesco's sales - stretching back to March 2015 - might be about to hit bottom, with the grocer possibly returning to growth in 2016.Going the other way, Hikma Pharmaceuticals slumped ahead of its interims on Wednesday. In a trading update on 4 August, the drug maker warned it expected full year core operating profit of its generics arm to be between $30m and $40m, compared to $46m in 2015.Hikma said at the time: "The revenue impact from the delay in certain new product approvals will be largely offset by higher contract manufacturing revenue."This change in the mix of revenue will have an adverse impact on profitability in 2016, which will also be impacted by higher than expected costs resulting from the acceleration in timing of certain pipeline-related litigation".Fellow pharmaceutical stocks Shire and Astrazeneca were also in the red.National Grid shares declined after energy regulator Ofgem rejected its request to recover costs incurred under a Drax contract as it failed to meet the test criteria.National Grid had been looking to recover the costs of two contracts for grid services that it agreed with SSE and Drax worth £113m in total.The request was made as an 'income adjusting event' where National Grid applies for an increase in its cost targets to cover unforeseen events beyond its control.But Ofgem has decided that costs the company incurred under the Drax contract did not meet the test for an 'income adjusting event'. FTSE 100 - RisersBarratt Developments (BDEV) 484.20p 4.47%Tesco (TSCO) 165.50p 3.76%Persimmon (PSN) 1,861.00p 3.73%Royal Bank of Scotland Group (RBS) 195.00p 3.61%Berkeley Group Holdings (The) (BKG) 2,638.00p 3.45%Anglo American (AAL) 862.40p 3.28%Travis Perkins (TPK) 1,631.00p 3.03%Taylor Wimpey (TW.) 163.50p 3.02%BHP Billiton (BLT) 1,063.00p 2.90%Standard Life (SL.) 359.30p 2.69%FTSE 100 - FallersMediclinic International (MDC) 1,064.00p -2.03%Compass Group (CPG) 1,487.00p -0.54%Royal Dutch Shell 'A' (RDSA) 1,891.00p -0.53%Shire Plc (SHP) 5,070.00p -0.49%CRH (CRH) 2,499.00p -0.36%London Stock Exchange Group (LSE) 2,880.00p -0.24%Royal Dutch Shell 'B' (RDSB) 1,969.50p -0.23%AstraZeneca (AZN) 5,084.00p -0.14%National Grid (NG.) 1,080.00p -0.09%3i Group (III) 624.50p -0.08%

Related Shares

More News
Today 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemi...

Today 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was ...

7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announ...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.